IL-PROJECT44
4.3.2020 13:02:09 CET | Business Wire | Press release
According to Gartner Inc.’s recently released Market Guide for Real-Time Transportation Visibility Platforms , visibility is only possible with comprehensive network coverage and compliance. Today project44, the global leader in advanced visibility for shippers and logistics service providers, announced a new service level agreement (SLA) around full truckload carrier onboarding. This groundbreaking agreement demonstrates the technology provider’s commitment to results and offers a money-back guarantee.
Under the new carrier coverage SLA, project44 will guarantee that 90% of a shipper’s contracted truckload carriers in North America and Europe will be live within 30 days of starting implementation. With carrier compliance at the foundation of transportation visibility, this commitment will rapidly deliver upon the promise of real-time visibility and provide project44 customers a significant competitive advantage in today’s Delivery Economy.
“Carrier network coverage is the linchpin to visibility. Uline evaluated a variety of technology providers and knew that our full truckload visibility implementation would fail without adequate network coverage. It was very clear to us that p44 provided the largest carrier network along with the most scalable and automated onboarding process,” said Angelo Ventrone, VP of Logistics at Uline, the leading distributor of shipping, industrial and packaging materials in North America. “As a partner, they went above and beyond to ensure compliance, which has resulted in truckload tracking percentages of over 95%. Ultimately selecting project44 has enabled Uline to efficiently deliver on a differentiated customer experience.”
While this service level agreement is new to the industry, project44’s commitment to its carrier network is not. The visibility provider serves over 300 enterprise customers with the largest carrier network across North America and Europe. This includes connections to more than 760 ELD/telematics providers over more than 48 countries, and connections to 4.33 million drivers, 3.55 million trucks, and 800,000 fleets. Thanks to its automated onboarding application, the Network Management Center™, project44 enables customers to accelerate their time to value and immediately see the results of their visibility investment.
“Coop operates with more than 1,000 stores who all need deliveries on a weekly basis. For us to have the most efficient supply chain, we lacked an end-to-end overview of our carrier and subcontractor deliveries,” said Kennet Thorsen, Senior Distribution Manager at Coop Denmark A/S. “Our organization leveraged project44’s robust carrier network and world-class onboarding process to rapidly increase the ROI of our technology investment, streamline operations and better meet service goals towards our stores.”
project44's Network Management Center debuted in Europe over three years ago, driving unprecedented time-to-live with Truckload carriers. 48% of carriers achieve live status within one day, 81% within ten days – all through an automated, self-service cloud-based application. By combining project44’s automated tools and enterprise-grade implementation processes, the world’s leading ecommerce retailer, utilizing more than 2,500 different truckload providers across Europe, saw 95% connectivity in the first 45 days of working with project44. The commitment outlined in this SLA provides shippers of all sizes with the tools necessary to compete with even the largest ecommerce companies.
“Carrier coverage is critical to seeing the ROI of visibility, and project44 is dedicated to quickly achieving high compliance percentages for our customers. It has been our goal from day one to build global and multimodal connectivity and serve as the supply chain ecosystem’s connective tissue. This SLA formalizes our commitment, ensuring the entire industry truly understands the power the right visibility solution can have on delivering rapid and enduring results for the world’s leading retailers, manufacturers and distributors,” stated Tommy Barnes, Head of Global Network Partnerships at project44.
By following project44’s implementation program and best practices, project44 will offer the 30-day onboarding SLA with a money back guarantee to shippers in North America and Europe. To learn more about the SLA and project44’s Advanced Visibility Platform™, contact the project44 team today .
About project44
project44 is the world’s only advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
